Evidence map›Paper›PMID 26554812›Full record

Observational studyBMC neurology2015

Making SENSE--Sustained Effort Network for treatment of Status Epilepticus as a multicenter prospective registry.

Christoph Kellinghaus, Nicolas Lang, Andrea O Rossetti, Stephan Rüegg, Christian Tilz, Eugen Trinka, Iris Unterberger, Zeljko Uzelac, Felix Rosenow

Open access · goldAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in BMC neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 17 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 9 institutions in 3 countries.

Christoph KellinghausDepartment of Neurology, Klinikum Osnabrück, Am Finkenhügel 1, D-49078, Osnabrück, Germany. christoph.kellinghaus@klinikum-os.de.
Nicolas LangDepartment of Neurology, University Hospital Schleswig-Holstein, Campus Kiel, D-24105, Kiel, Germany. n.lang@neurologie.uni-kiel.de.
Andrea O RossettiDepartment of Clinical Neurosciences, CHUV and University of Lausanne, CH-1011, Lausann, Switzerland. andrea.rossetti@chuv.ch.
Stephan RüeggDepartment of Neurology, University Hospital Basel, Petersgraben 4, CH-4031, Basel, Switzerland. stephan.rueegg@usb.ch.
Christian TilzDepartment of Neurology, Krankenhaus Barmherzige Brüder Regensburg, Prüfeninger Str. 86, D-93049, Regensburg, Germany. christian.tilz@barmherzige-regensburg.de.
Eugen TrinkaDepartment of Neurology, Christian Doppler Klinik of Paracelsus Medical University, Ignaz Harrerstarsse 79, A-5020, Salzburg, Austria. e.trinka@salk.at.
Iris UnterbergerDepartment of Neurology, Innsbruck Medical University, Anichstrasse 35, A-6020, Innsbruck, Austria. iris.unterberger@i-med.ac.at.
Zeljko UzelacDepartment of Neurology, University Hospital Ulm, Oberer Eselsberg 45, D-89081, Ulm, Germany. zeljkou@gmail.com.
Felix RosenowEpilepsy Center Hessen - Marburg, Department of Neurology, University Hospitals and Philipps-University Marburg, Rudolf-Bultmann-Strasse 8, D-35039, Marburg, Germany. rosenow@med.uni-marburg.de.
Innsbruck Medical University · ATKlinikum Osnabrück · DEKrankenhaus Barmherzige Brüder · DEParacelsus Medical University · ATPhilipps University of Marburg · DEUniversity Hospital of Basel · CHUniversity Hospital Ulm · DEUniversity of Lausanne · CHUniversity of Lübeck · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEvidence regarding the different treatment options of status epilepticus (SE) in adults is scarce. Large randomized trials cover only one treatment at early stage and suggest the superiority of benzodiazepines over placebo, of intravenous lorazepam over intravenous diazepam or over intravenous phenytoin alone, and of intramuscular midazolam over intravenous lorazepam. However, many patients will not be treated successfully with the first treatment step. A large randomized trial covering the treatment of established status (ESETT) has just been funded recently by the NIH and will not start before 2015, with expected results in 2018; a trial on the treatment of refractory status with general anesthetics was terminated early due to insufficient recruitment. Therefore, a prospective multicenter observational registry was set up; this may help in clinical decision-making until results from randomized trials are available. METHODS/

designSENSE is a prospective, multicenter registry for patients treated for SE. The primary objective is to document patient characteristics, treatment modalities and in-house outcome of consecutive adults admitted for SE treatment in each of the participating centres and to identify predictors of outcome. Pre-treatment, treatment-related and outcome variables are documented systematically. To allow for meaningful multivariate analysis in the patient subgroups with refractory SE, a cohort size of 1000 patients is targeted. DISCUSSION: The results of the study will provide information about risks and benefits of specific treatment steps in different patient groups with SE at different points of time. Thus, it will support clinical decision-making and, furthermore, it will be helpful in the planning of treatment trials.

trial registrationDRKS00000725.

Indexed as

RegistriesAdultAgedAnticonvulsantsDiazepamFemaleHumansLorazepamMaleMidazolamMiddle AgedPhenytoinProspective StudiesStatus EpilepticusAnticonvulsantsDiazepamLorazepamMidazolamPhenytoin

Identifiers

PMID26554812
PMCPMC4641362
OpenAlexW2144547665

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.